CPT code 62361 covers implantation or replacement of a nonprogrammable subcutaneous pump used for continuous intrathecal or epidural infusion of medications. This procedure is clinically significant for management of refractory chronic pain, spasticity, and for targeted delivery of chemotherapeutic agents, offering an alternative route that can reduce systemic side effects and improve symptom control. Nationally, these implant procedures intersect with surgical, pain-management, and oncology care pathways and are subject to payer coverage policies and site-of-service considerations.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The report outlines typical clinical indications, procedural and site-of-service context, and what to expect from payer coverage patterns. Readers will find benchmarks for utilization and reimbursement context where available, summaries of relevant policy trends affecting access and prior authorization, and practical clinical context about device purpose and common applications. Data limitations are noted where input lacked specifics.

This summary is intended for clinicians, coding and billing professionals, and policy analysts seeking a concise national overview of CPT code 62361, its clinical role, and the payer landscape that influences access to implantable intrathecal/epidural pump therapy.